The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer

January 23, 2019
In recent years, researchers have been looking into using a class of drugs called PARP inhibitors to prevent the progression and recurrence of ovarian cancer. Dr. Kathleen Moore of Stephenson Cancer Center, Principal Investigator of the SOLO-1 trial, explains how the results of this trial may affect ovarian cancer patients and where research on ovarian cancer treatment is headed next.


National Helpline:
844-ASK-SHARE